It did years ago. But in recent years it has had so many setbacks, clinically and financially driven, that the possibility of company failure is real. Leo is doing his best to prevent that but finding a partner or a financier is now proving very difficult. This is what it looks like when a biotech is struggling. We're down to a few employees, reducing our offices, giving up IP rights, and not knowing if we can stay operating another month. The market thinks there's a very slim chance of survival (we'd be down even farther if it felt there was no chance), and it's right, as it always inevitably is. Doesn't mean Leo doesn't get a deal, just means the odds are not in our favor.
Leo has admitted to a poster here that we have financial issues, not that the 10Q isn't proof enough. And he said no BP is interested in B. ("They want cancer drugs." No, they want promising drugs.)
Hopefully there's a Tier 2 pharma about to pull the trigger on us, because the market is getting ready to pull the plug. Fingers crossed everyone!
News 
Market Data 
Discover 
AI
